SebastianBöttcher

Prof. Dr. med. Sebastian Böttcher

Universitätsmedizin Rostock

Medizinische Klinik III für Hämatologie, Onkologie und Palliativmedizin
 

Contact

 
Ernst-Heydemann-Straße 6
18057 Rostock
 
+49 381 494-7405
 

Literature

Original publications

  1. Stilgenbauer S, Bosch F, Ilhan O, Kisro J, Mahé B, Mikuskova E, Osmanov D, Reda G, Robinson S, Tausch E, Turgut M, Wójtowicz M, Böttcher S, Perretti T, Trask P, Van Hoef M, Leblond V, Foà R. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. Br J Haematol. 2021;193: 325-38.
  2. Fürstenau M, Fink AM, Schilhabel A, Weiss J, Robrecht S, Eckert R, de la Serna J, Crespo M, Coscia M, Vitale C, Böttcher S, Weppner G, Ritgen M, Stilgenbauer S, Tausch E, Fischer K, Hallek M, Eichhorst B, Brüggemann M, Herling CD. B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. 2021;137: 2267-71.
  3. Cramer, P., J, V.T., Robrecht, S., Bahlo, J., Furstenau, M., Langerbeins, P., Pflug, N., Al-Sawaf, O., Heinz, W.J., Vehling-Kaiser, U., Durig, J., Tausch, E., Hensel, M., Sasse, S., Fink, A.M., Fischer, K., Kreuzer, K.A., Bottcher, S., Ritgen, M., Kneba, M., Wendtner, C.M., Stilgenbauer, S., Eichhorst, B., Hallek, M. (2021). Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial. Haematologica. 106:543-554
  4. Pouyiourou M, Meyer A, Stroux A, Viardot A, La Rosée P, Maschmeyer G, Kämpfe D, Kahl C, Vucinic V, Monecke A, Hirt C, Weber T, Meissner J, Witzens-Harig M, Böttcher S, Schmalenberg H, Marks R, Prange-Krex G, Kroschinsky F, Hauf E, Keller U, Koch K, Klapper W, Herold M, Scholz CW. First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis. Ann Hematol. 2020;99:2821-9.
  5. Patil, P., Cieslak, A., Bernhart, S.H., Toprak, U.H., Wagener, R., Lopez, C., Wiehle, L., Bens, S., Altmuller, J., Franitza, M., Scholz, I., Jayne, S., Ahearne, M.J., Scheffold, A., Jebaraj, B.M.C., Schneider, C., Costa, D., Braun, T., Schrader, A., Campo, E., Dyer, M.J.S., Nurnberg, P., Durig, J., Johansson, P., Bottcher, S., Schlesner, M., Herling, M., Stilgenbauer, S., Macintyre, E., Siebert, R. (2020). Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia. Genes, chromosomes & cancer 59: 261-267.
  6. Kutsch, N., Bahlo, J., Robrecht, S., Franklin, J., Zhang, C., Maurer, C., De Silva, N., Lange, E., Weide, R., Kiehl, M.G., Sokler, M., Schlag, R., Vehling-Kaiser, U., Kochling, G., Ploger, C., Gregor, M., Plesner, T., Herling, M., Fischer, K., Dohner, H., Kneba, M., Wendtner, C.M., Klapper, W., Kreuzer, K.A., Bottcher, S., Stilgenbauer, S., Fink, A.M., Hallek, M., Eichhorst, B. (2020). Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG). HemaSphere 4: e336.
  7. Herling, C.D., Cymbalista, F., Gross-Ophoff-Muller, C., Bahlo, J., Robrecht, S., Langerbeins, P., Fink, A.M., Al-Sawaf, O., Busch, R., Porcher, R., Cazin, B., Dreyfus, B., Ibach, S., Lepretre, S., Fischer, K., Kaiser, F., Eichhorst, B., Wentner, C.M., Hoechstetter, M.A., Dohner, H., Leblond, V., Kneba, M., Letestu, R., Bottcher, S., Stilgenbauer, S., Hallek, M., Levy, V. (2020). Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia. 34: 2038-2050
  8. Furstenau, M., Bahlo, J., Fink, A.M., Lange, E., Dreger, P., Dreyling, M., Hess, G., Ritgen, M., Kneba, M., Dohner, H., Stilgenbauer, S., Wendtner, C.M., Goede, V., Fischer, K., Bottcher, S., Hallek, M., Eichhorst, B. (2020). Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia. Leukemia 34: 924-928.
  9. Bosch, F., Cantin, G., Cortelezzi, A., Knauf, W., Tiab, M., Turgut, M., Zaritskey, A., Merot, J.L., Tausch, E., Trunzer, K., Robson, S., Gresko, E., Bottcher, S., Foa, R., Stilgenbauer, S., Leblond, V. (2020). Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. Leukemia 34: 441-450..
  10. Novakova, M., Glier, H., Brdickova, N., Vlkova, M., Santos, A.H., Lima, M., Roussel, M., Flores-Montero, J., Szczepanski, T., Bottcher, S., van der Velden, V.H.J., Fernandez, P., Mejstrikova, E., Burgos, L., Paiva, B., van Dongen, J.J.M., Orfao, A., Kalina, T. (2019). How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers. J Immunol Methods 475: 112388.
  11. Jebaraj, B.M.C., Tausch, E., Landau, D.A., Bahlo, J., Robrecht, S., Taylor-Weiner, A.N., Bloehdorn, J., Scheffold, A., Mertens, D., Bottcher, S., Kneba, M., Jager, U., Zenz, T., Wenger, M.K., Fingerle-Rowson, G., Wendtner, C., Fink, A.M., Wu, C.J., Eichhorst, B., Fischer, K., Hallek, M., Dohner, H., Stilgenbauer, S. (2019). Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. Leukemia  33: 2183-2194
  12. Flores-Montero, J., Grigore, G., Fluxa, R., Hernandez, J., Fernandez, P., Almeida, J., Munoz, N., Bottcher, S., Sedek, L., van der Velden, V., Barrena, S., Hernandez, A., Paiva, B., Lecrevisse, Q., Lima, M., Santos, A.H., van Dongen, J.J.M., Orfao, A. (2019). EuroFlow Lymphoid Screening Tube (LST) data base for automated identification of blood lymphocyte subsets. J Immunol Methods 475: 112662.
  13. Fischer, K., Al-Sawaf, O., Bahlo, J., Fink, A.M., Tandon, M., Dixon, M., Robrecht, S., Warburton, S., Humphrey, K., Samoylova, O., Liberati, A.M., Pinilla-Ibarz, J., Opat, S., Sivcheva, L., Le Du, K., Fogliatto, L.M., Niemann, C.U., Weinkove, R., Robinson, S., Kipps, T.J., Boettcher, S., Tausch, E., Humerickhouse, R., Eichhorst, B., Wendtner, C.M., Langerak, A.W., Kreuzer, K.A., Ritgen, M., Goede, V., Stilgenbauer, S., Mobasher, M., Hallek, M. (2019). Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med 380: 2225-2236.
  14. Bottcher, S., van der Velden, V.H.J., Villamor, N., Ritgen, M., Flores-Montero, J., Escobar, H.M., Kalina, T., Bruggemann, M., Grigore, G., Martin-Ayuso, M., Lecrevisse, Q., Pedreira, C.E., van Dongen, J.J.M., Orfao, A. (2019). Lot-to-lot stability of antibody reagents for flow cytometry. J Immunol Methods 475: 112294.
  15. von Tresckow, J., Cramer, P., Bahlo, J., Robrecht, S., Langerbeins, P., Fink, A.M., Al-Sawaf, O., Illmer, T., Klaproth, H., Estenfelder, S., Ritgen, M., Fischer, K., Wendtner, C.M., Kreuzer, K.A., Stilgenbauer, S., Böttcher, S., Eichhorst, B.F., Hallek, M. (2019). CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia 33: 1161-1172.
  16. Schetelig, J., Link, C.S., Stuhler, G., Wagner, E.M., Hanel, M., Kobbe, G., Böttcher, S., Kreuzer, K.A., Middeke, J.M., Sockel, K., Teipel, R., von Bonin, M., Stolzel, F., Kramer, M., Stilgenbauer, S., Hallek, M., Bornhauser, M. (2019). Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial. Br J Haematol 184: 833-836.
  17. Langerak, A.W., Ritgen, M., Goede, V., Robrecht, S., Bahlo, J., Fischer, K., Steurer, M., Trneny, M., Mulligan, S.P., Mey, U.J.M., Trunzer, K., Fingerle-Rowson, G., Humphrey, K., Stilgenbauer, S., Böttcher, S., Bruggemann, M., Hallek, M., Kneba, M., van Dongen, J.J.M. (2019). Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. Blood 133: 494-497.
  18. Kurtz, D.M., Esfahani, M.S., Scherer, F., Soo, J., Jin, M.C., Liu, C.L., Newman, A.M., Duhrsen, U., Huttmann, A., Casasnovas, O., Westin, J.R., Ritgen, M., Böttcher, S., Langerak, A.W., Roschewski, M., Wilson, W.H., Gaidano, G., Rossi, D., Bahlo, J., Hallek, M., Tibshirani, R., Diehn, M., Alizadeh, A.A. (2019). Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. Cell 178: 699-713.e619.
  19. Fischer, K., Al-Sawaf, O., Bahlo, J., Fink, A.M., Tandon, M., Dixon, M., Robrecht, S., Warburton, S., Humphrey, K., Samoylova, O., Liberati, A.M., Pinilla-Ibarz, J., Opat, S., Sivcheva, L., Le Du, K., Fogliatto, L.M., Niemann, C.U., Weinkove, R., Robinson, S., Kipps, T.J., Boettcher, S., Tausch, E., Humerickhouse, R., Eichhorst, B., et al. (2019). Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med 380: 2225-2236.
  20. Stilgenbauer, S., Leblond, V., Foa, R., Böttcher, S., Ilhan, O., Knauf, W., Mikuskova, E., Renner, C., Tausch, E., Woszczyk, D., Gresko, E., Lundberg, L., Moore, T., Morris, T., Robson, S., Bosch, F. (2018). Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. Leukemia 32: 1778-1786.
  21. Stilgenbauer, S., Eichhorst, B., Schetelig, J., Hillmen, P., Seymour, J.F., Coutre, S., Jurczak, W., Mulligan, S.P., Schuh, A., Assouline, S., Wendtner, C.M., Roberts, A.W., Davids, M.S., Bloehdorn, J., Munir, T., Böttcher, S., Zhou, L., Salem, A.H., Desai, M., Chyla, B., Arzt, J., Kim, S.Y., Verdugo, M., Gordon, G., et al. (2018). Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol 36: 1973-1980.
  22. Cramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Langerbeins, P., Al-Sawaf, O., Engelke, A., Fink, A.M., Fischer, K., Tausch, E., Seiler, T., Fischer von Weikersthal, L., Hebart, H., Kreuzer, K.A., Böttcher, S., Ritgen, M., Kneba, M., Wendtner, C.M., Stilgenbauer, S., Eichhorst, B., and Hallek, M. (2018). Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19: 1215-1228.
  23. García-Barchino MJ, Sarasquete ME, Panizo C, Morscio J, Martinez A, Alcoceba M, Fresquet V, Gonzalez-Farre B, Paiva B, Young KH, Robles EF, Roa S, Celay J, Larrayoz M, Rossi D, Gaidano G, Montes-Moreno S, Piris MA, Balanzategui A, Jimenez C, Rodriguez I, Calasanz MJ, Larrayoz MJ, Segura V, Garcia-Muñoz R, Rabasa MP, Yi S, Li J, Zhang M, Xu-Monette ZY, Puig-Moron N, Orfao A, Böttcher S, Hernandez-Rivas JM, Miguel JS, Prosper F, Tousseyn T, Sagaert X, Gonzalez M, Martinez-Climent JA. (2018). Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia. J Pathol. 245: 61-73
  24. Dimier N, Delmar P, Ward C, Morariu-Zamfir R, Fingerle-Rowson G, Bahlo J, Fischer K, Eichhorst B, Goede V, van Dongen JJM, Ritgen M, Böttcher S, Langerak AW, Kneba M, Hallek M.(2018) A model for predicting effect of treatment on progression-free survival using MRD as a surrogate endpoint in CLL. Blood. 131:955-962
  25. Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M. (2017) Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 4:e475-e486
  26. Krämer I, Stilgenbauer S, Dietrich S, Böttcher S, Zeis M, Stadler M, Bittenbring J, Uharek L, Scheid C, Hegenbart U, Ho A, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P. (2017) Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood.130:1477-1480
  27. Böttcher, S., van der Velden, V.H.J., Villamor, N., Ritgen, M., Flores-Montero, J., Murua Escobar, H., Kalina, T., Bruggemann, M., Grigore, G., Martin-Ayuso, M., Lecrevisse, Q., Pedreira, C.E., van Dongen, J.J.M., and Orfao, A. (2017). Lot-to-lot stability of antibody reagents for flow cytometry. Journal of immunological methods. Epub ahead of print
  28. Fischer, K., Al-Sawaf, O., Fink, A.M., Dixon, M., Bahlo, J., Warburton, S., Kipps, T.J., Weinkove, R., Robinson, S., Seiler, T., Opat, S., Owen, C., Lopez, J., Humphrey, K., Humerickhouse, R., Tausch, E., Frenzel, L., Eichhorst, B., Wendtner, C.M., Stilgenbauer, S., Langerak, A.W., van Dongen, J.J.M., Böttcher, S., Ritgen, M., et al. (2017). Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 129:2702-2705.
  29. Flores-Montero, J., Sanoja-Flores, L., Paiva, B., Puig, N., Garcia-Sanchez, O., Böttcher, S., van der Velden, V.H., Perez-Moran, J.J., Vidriales, M.B., Garcia-Sanz, R., Jimenez, C., Gonzalez, M., Martinez-Lopez, J., Corral-Mateos, A., Grigore, G.E., Fluxa, R., Pontes, R., Caetano, J., Sedek, L., Del Canizo, M.C., Blade, J., Lahuerta, J.J., Aguilar, C., Barez, A., et al. (2017). Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 31:2094-2103
  30. Braig F, Brandt A, Goebeler M, Tony HP, Kurze AK, Nollau P, Bumm T, Böttcher S, Bargou RC, Binder M. (2017) Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood. 129:100-104
  31. Al-Sawaf O, Fischer K, Herling CD, Ritgen M, Böttcher S, Bahlo J, Elter T,Stilgenbauer S, Eichhorst BF, Busch R, Elberskirch U, Abenhardt W, Kneba M, Hallek M, Wendtner CM. (2017) Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. Eur J Haematol. 98:254-262
  32. Edelmann J, Tausch E, Landau D, Robrecht S, Bahlo J, Fischer K, Fink A, Bloehdorn, Holzmann K, Böttcher S, Werner L, Kneba M, Gribben J, Neuberg D, Wu C, Hallek M, Dohner H, Stilgenbauer S (2017) Frequent evolution of copy number alterations in CLL following first line treatment with FC(R) is enriched with TP53 alterations: Results from the CLL8 trial. Leukemia. 31:734-738
  33. Scheffold A, Jebaraj B, Tausch E, Steinbrecher D, Hahn M, Böttcher S, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P, Stilgenbauer S (2017) Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukemia: results from the GSLLSG CLL3X trial. Br J Haematol. 179:342-346
  34. Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, Maurer C, Langerbeins P, Fingerle-Rowson G, Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Klapper W, Wendtner C, Fischer K, Hallek M, Eichhorst B*, Böttcher S* (2016) Minimal Residual Disease Assessment Improves Prediction of Outcome in Chronic Lymphocytic Leukemia (CLL) Patients Achieving Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG). J Clin Oncol. 34:3758-3765 *shared senior authorship
  35. Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Koppler H, Kiehl M, Sokler M, Schlag R, Vehling-Kaiser U, Kochling G, Ploger C, Gregor M, Plesner T, Trneny M, Fischer K, Dohner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M (2016) First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 17: 928-42
  36. Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG (2016) Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 17:768-78
  37. Freeman CL, Dixon M, Houghton R, Kreuzer KA, Fingerle-Rowson G, Herling M, Humphrey K, Böttcher S, de Costa CS, Iglesias V, Stilgenbauer S, Gribben J, Hallek M, Goede V (2016) Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab. Leukemia. 30:1763-6
  38. Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von TJ, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer KA, Eichhorst B, Böttcher S, Seymour JF, Ghia P, Marlton P, Kneba M, Wendtner CM, Dohner H, Stilgenbauer S, Hallek M (2016) Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 127: 208-215.
  39. Pojero F, Flores-Montero J, Sanoja L, Perez JJ, Puig N, Paiva B, Böttcher S, van Dongen JJ, Orfao A (2016) Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases. Cytometry B 90: 91-100.
  40. Hahn M, Böttcher S, Dietrich S, Hegenbart U, Rieger M, Stadtherr P, Bondong A, Schulz R, Ritgen M, Schmitt T, Tran TH, Gorner M, Herth I, Luft T, Schonland S, Witzens-Harig M, Zenz T, Kneba M, Ho AD, Dreger P (2015) Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse. Bone Marrow Transplant 50: 1279-1285.
  41. Maurer C, Pflug N, Bahlo J, Kluth S, Rhein C, Cramer P, Gross-Ophoff C, Langerbeins P, Fink AM, Eichhorst B, Kreuzer KA, Fischer N, Tausch E, Stilgenbauer S, Böttcher S, Dohner H, Kneba M, Dreyling M, Binder M, Hallek M, Wendtner CM, Bergmann M, Fischer K (2016) Bendamustine and Rituximab in Combination with Lenalidomide in Patients with Chronic Lymphocytic Leukemia. Eur J Haematol. 97: 253-60.
  42. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, Carter SL, Cibulskis K, Mertens D, Sougnez CL, Rosenberg M, Hess JM, Edelmann J, Kless S, Kneba M, Ritgen M, Fink A, Fischer K, Gabriel S, Lander ES, Nowak MA, Dohner H, Hallek M, Neuberg D, Getz G, Stilgenbauer S, Wu CJ (2015) Mutations driving CLL and their evolution in progression and relapse. Nature 526: 525-530.
  43. Barcena P, Jara-Acevedo M, Tabernero MD, Lopez A, Sanchez ML, Garcia-Montero AC, Munoz-Garcia N, Vidriales MB, Paiva A, Lecrevisse Q, Lima M, Langerak AW, Böttcher S, van Dongen JJ, Orfao A, Almeida J (2015) Phenotypic profile of expanded NK cells in chronic lymphoproliferative disorders: a surrogate marker for NK-cell clonality. Oncotarget 6: 42938-42951.
  44. Kalina T, Flores-Montero J, Lecrevisse Q, Pedreira CE, van der Velden VH, Novakova M, Mejstrikova E, Hrusak O, Böttcher S, Karsch D, Sedek L, Trinquand A, Boeckx N, Caetano J, Asnafi V, Lucio P, Lima M, Helena SA, Bonaccorso P, van der Sluijs-Gelling AJ, Langerak AW, Martin-Ayuso M, Szczepanski T, van Dongen JJ, Orfao A (2015) Quality assessment program for EuroFlow protocols: summary results of four-year (2010-2013) quality assurance rounds. Cytometry A 87: 145-156.
  45. van der Velden VH, Hoogeveen PG, de Ridder D, Schindler-van der Struijk M, Van Zelm MC, Sanders M, Karsch D, Beverloo HB, Lam K, Orfao A, Lugtenburg PJ, Böttcher S, van Dongen JJ, Langerak AW, Kappers-Klunne M, van Lom K (2014) B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma. Blood 124: 412-419.
  46. Berkowska MA, Grosserichter-Wagener C, Adriaansen HJ, de Ridder D, Mirani-Oostdijk KP, Agteresch HJ, Böttcher S, Orfao A, van Dongen JJ, Van Zelm MC (2014) Persistent polyclonal B-cell lymphocytosis: extensively proliferated CD27+IgM+IgD+ memory B cells with a distinctive immunophenotype. Leukemia 28: 1560-1564.
  47. Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Dohner K, Buhler A, Böttcher S, Ritgen M, Kneba M, Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, Jager U, Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch R, Hallek M, Dohner H (2014) Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 123: 3247-3254.
  48. Dreger P, Schnaiter A, Zenz T, Böttcher S, Rossi M, Paschka P, Buhler A, Dietrich S, Busch R, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Dohner H, Stilgenbauer S (2013) TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood 121: 3284-3288.
  49. Fink AM*, Böttcher S*, Ritgen M, Fischer K, Pflug N, Eichhorst B, Wendtner CM, Winkler D, Buhler A, Zenz T, Staib P, Mayer J, Hensel M, Hopfinger G, Wenger M, Fingerle-Rowson G, Dohner H, Kneba M, Stilgenbauer S, Busch R, Hallek M (2013) Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. Leukemia 27: 1949-1952. *shared first authorship
  50. Gahn B, Staudinger M, Woester K, Wellnitz D, Böttcher S, Gramatzki M, Kneba M (2013) In vitro activation of hTERT-specific T cell responses in lung cancer patients following chemotherapy. J Thorac Dis 5: 240-250.
  51. Giefing M, Winoto-Morbach S, Sosna J, Doring C, Klapper W, Kuppers R, Böttcher S, Adam D, Siebert R, Schutze S (2013) Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma show alterations of genes encoding the NADPH oxidase complex and impaired reactive oxygen species synthesis capacity. PLoS One 8: e84928.
  52. Rawstron AC, Böttcher S, Letestu R, Villamor N, Fazi C, Kartsios H, de Tute RM, Shingles J, Ritgen M, Moreno C, Lin K, Pettitt AR, Kneba M, Montserrat E, Cymbalista F, Hallek M, Hillmen P, Ghia P (2013) Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 27: 142-149.
  53. Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch R, Fingerle-Rowson G, Fink AM, Bühler A, Zenz T, Wenger M, Mendila M, Wendtner CM, Eichhorst B, Döhner H, Hallek M, Kneba M (2012) Minimal residual disease quantification is an independent predictor of progression free and overall survival in chronic lymphocytic leukemia. A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 30: 980-988.
  54. Dekking EH, van der Velden VH, Varro R, Wai H, Böttcher S, Kneba M, Sonneveld E, Koning A, Boeckx N, Van PN, Lucio P, Mendonca A, Sedek L, Szczepanski T, Kalina T, Kanderova V, Hoogeveen P, Flores-Montero J, Chillon MC, Orfao A, Almeida J, Evans P, Cullen M, Noordijk AL, Vermeulen PM, de Man MT, Dixon EP, Comans-Bitter WM, van Dongen JJ (2012) Flow cytometric immunobead assay for fast and easy detection of PML-RARA fusion proteins for the diagnosis of acute promyelocytic leukemia. Leukemia 26: 1976-1985.
  55. Elter T, James R, Busch R, Winkler D, Ritgen M, Böttcher S, Kahl C, Gassmann W, Stauch M, Hasan I, Staib P, Fischer K, Fink AM, Bahlo J, Buhler A, Dohner H, Wendtner CM, Stilgenbauer S, Engert A, Hallek M (2012) Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia 26: 2549-2552.
  56. Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, Pfluger KH, Schott S, Goede V, Isfort S, von Tresckow J, Fink AM, Buhler A, Winkler D, Kreuzer KA, Staib P, Ritgen M, Kneba M, Dohner H, Eichhorst BF, Hallek M, Stilgenbauer S, Wendtner CM (2012) Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 30: 3209-3216.
  57. van Dongen JJ, Lhermitte L, Böttcher S, Almeida J, van der Velden VH, Flores-Montero J, Rawstron A, Asnafi V, Lecrevisse Q, Lucio P, Mejstrikova E, Szczepanski T, Kalina T, de Tute R, Bruggemann M, Sedek L, Cullen M, Langerak AW, Mendonca A, Macintyre E, Martin-Ayuso M, Hrusak O, Vidriales MB, Orfao A (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26: 1908-1975.
  58. Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Böttcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Buhler A, Winkler D, Kneba M, Dohner H, Eichhorst BF, Hallek M, Wendtner CM (2011) Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 29: 3559-3566.
  59. Costa ES, Pedreira CE, Barrena S, Lecrevisse Q, Flores J, Quijano S, Almeida J, Del CG-M, Böttcher S, van Dongen JJ, Orfao A (2010) Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping. Leukemia 24: 1927-1933.
  60. Dreger P, Dohner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, Hasenkamp J, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek M, Kneba M, Schmitz N, Stilgenbauer S (2010) Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 116: 2438-2447.
  61. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von GU, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376: 1164-1174.
  62. Pott C, Hoster E, Delfau-Larue MH, Beldjord K, Böttcher S, Asnafi V, Plonquet A, Siebert R, Callet-Bauchu E, Andersen N, van Dongen JJ, Klapper W, Berger F, Ribrag V, van Hoof AL, Trneny M, Walewski J, Dreger P, Unterhalt M, Hiddemann W, Kneba M, Kluin-Nelemans HC, Hermine O, Macintyre E, Dreyling M (2010) Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 115: 3215-3223.
  63. Böttcher S, Stilgenbauer S, Busch R, Bruggemann M, Raff T, Pott C, Fischer K, Fingerle-Rowson G, Dohner H, Hallek M, Kneba M, Ritgen M (2009) Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia 23: 2007-2017.
  64. Nagel I, Akasaka T, Klapper W, Gesk S, Böttcher S, Ritgen M, Harder L, Kneba M, Dyer MJ, Siebert R (2009) Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma. Haematologica 94: 1020-1023.
  65. Weerkamp F, Dekking E, Ng YY, van der Velden VH, Wai H, Böttcher S, Bruggemann M, van der Sluijs AJ, Koning A, Boeckx N, Van PN, Lucio P, Mendonca A, Sedek L, Szczepanski T, Kalina T, Kovac M, Hoogeveen PG, Flores-Montero J, Orfao A, Macintyre E, Lhermitte L, Chen R, Brouwer-De Cock KA, van der Linden A, Noordijk AL, Comans-Bitter WM, Staal FJ, van Dongen JJ (2009) Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients. Leukemia 23: 1106-1117.
  66. Böttcher S, Ritgen M, Buske S, Gesk S, Klapper W, Hoster E, Hiddemann W, Unterhalt M, Dreyling M, Siebert R, Kneba M, Pott C (2008) Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica 93: 551-559.
  67. Ritgen M, Böttcher S, Stilgenbauer S, Bunjes D, Schubert J, Cohen S, Humpe A, Hallek M, Kneba M, Schmitz N, Dohner H, Dreger P (2008) Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia 22: 1377-1386.
  68. Raff T, Gokbuget N, Luschen S, Reutzel R, Ritgen M, Irmer S, Böttcher S, Horst HA, Kneba M, Hoelzer D, Bruggemann M (2007) Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 109: 910-915.
  69. Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, Evans PA, Natkunam Y, Coutre SE, Avery ED, Rassenti LZ, Kipps TJ, Caligaris-Cappio F, Kneba M, Byrd JC, Hallek MJ, Montserrat E, Hillmen P (2007) International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21: 956-964.
  70. Moosig F, Fahndrich E, Knorr-Spahr A, Böttcher S, Ritgen M, Zeuner R, Kneba M, Schroder JO (2006) C1qRP (CD93) expression on peripheral blood monocytes in patients with systemic lupus erythematosus. Rheumatol Int 26: 1109-1112.
  71. Letestu R, Rawstron A, Ghia P, Villamor N, Leuven NB, Böttcher S, Buhl AM, Duerig J, Ibbotson R, Kroeber A, Langerak A, Garff-Tavernier M, Mockridge I, Morilla A, Padmore R, Rassenti L, Ritgen M, Shehata M, Smolewski P, Staib P, Ticchioni M, Walker C, Ajchenbaum-Cymbalista F (2006) Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process. Cytometry B 70: 309-314.
  72. Zenz T, Ritgen M, Dreger P, Krober A, Barth TF, Schlenk R, Böttcher S, Hallek MJ, Kneba M, Bunjes D, Dohner H, Stilgenbauer S (2006) Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 108: 2127-2130.
  73. Böttcher S, Ritgen M, Bruggemann M, Raff T, Luschen S, Humpe A, Kneba M, Pott C (2005) Flow cytometric assay for determination of FcgammaRIIIA-158 V/F polymorphism. J Immunol Methods 306: 128-136.
  74. Böttcher S, Ritgen M, Pott C, Bruggemann M, Raff T, Stilgenbauer S, Dohner H, Dreger P, Kneba M (2004) Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 18: 1637-1645.
  75. Moosig F, Graf D, Knorr-Spahr A, Zeuner RA, Böttcher S, Schroder JO (2003) Monocyte and granulocyte phagocytosis of Escherichia coli particles in systemic lupus erythematosus is not reduced when compared to healthy controls. Lupus 12: 490-492.
  76. Schenk TM, Keyhani A, Böttcher S, Kliche KO, Goodacre A, Guo JQ, Arlinghaus RB, Kantarjian HM, Andreeff M (1998) Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia 12: 666-674.

 

 

Reviews:

  1. Skusa C, Weber MA, Böttcher S, Thierfelder KM. Criteria-Based Imaging and Response Evaluation of Lymphoma 20 Years After Cheson: What is New? RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. 2020;192:657-68.
  2. Böttcher, S. (2019). Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies. Methods Mol Biol 1956: 157-197.
  3. Böttcher, S. (2019). Minimal Residual Disease Quantification in Chronic Lymphocytic Leukemia: Clinical Significance and Flow Cytometric Methods. Methods Mol Biol 1881: 211-238.
  4. Flores-Montero, J., Kalina, T., Corral-Mateos, A., Sanoja-Flores, L., Perez-Andres, M., Martin-Ayuso, M., Sedek, L., Rejlova, K., Mayado, A., Fernandez, P., van der Velden, V., Böttcher, S., van Dongen, J.J.M., Orfao, A. (2019). Fluorochrome choices for multi-color flow cytometry. J Immunol Methods. Epub ahead of print
  5. Ladetto, M., Böttcher, S., Kroger, N., Pulsipher, M.A., Bader, P. (2019). Methods and role of minimal residual disease after stem cell transplantation. Bone Marrow Transplant 54: 681-690.
  6. Cramer, P., von Tresckow, J., Bahlo, J., Engelke, A., Langerbeins, P., Fink, A.M., Fischer, K., Wendtner, C.M., Kreuzer, K.A., Stilgenbauer, S., Böttcher, S., Eichhorst, B., Hallek, M. (2018). CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future oncology (London, England) 14: 499-513.
  7. Novakova, M., Glier, H., Brdickova, N., Vlkova, M., Santos, A.H., Lima, M., Roussel, M., Flores-Montero, J., Szczepanski, T., Böttcher, S., van der Velden, V.H.J., Fernandez, P., Mejstrikova, E., Burgos, L., Paiva, B., van Dongen, J.J.M., Orfao, A., Kalina, T. (2017). How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers. J Immunol Methods. Epub ahead of print
  8. Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A (2015) Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B 90: 61-72.
  9. Böttcher S (2014) Paving the road to MRD-guided treatment in CLL. Blood 123: 3683-3684.
  10. Böttcher S, Hallek M, Ritgen M, Kneba M (2013) The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time? Hematol Oncol Clin North Am 27: 267-288.
  11. Kalina T, Flores-Montero J, van der Velden VH, Martin-Ayuso M, Böttcher S, Ritgen M, Almeida J, Lhermitte L, Asnafi V, Mendonca A, de TR, Cullen M, Sedek L, Vidriales MB, Perez JJ, te Marvelde JG, Mejstrikova E, Hrusak O, Szczepanski T, van Dongen JJ, Orfao A (2012) EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 26: 1986-2010.
  12. Böttcher S, Ritgen M, Dreger P (2011) Allogeneic stem cell transplantation for chronic lymphocytic leukemia: Lessons to be learned from minimal residual disease studies. Blood Rev 25: 91-96.
  13. Dekking E, van der Velden VH, Böttcher S, Bruggemann M, Sonneveld E, Koning-Goedheer A, Boeckx N, Lucio P, Sedek L, Szczepanski T, Kalina T, Kovac M, Evans P, Hoogeveen PG, Flores-Montero J, Orfao A, Comans-Bitter WM, Staal FJ, van Dongen JJ (2010) Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay. Best Pract Res Clin Haematol 23: 333-345.
  14. Kroger N, Bacher U, Bader P, Böttcher S, Borowitz MJ, Dreger P, Khouri I, Macapinlac HA, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS (2010) NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant 16: 1187-1211.
  15. Kroger N, Bacher U, Bader P, Böttcher S, Borowitz MJ, Dreger P, Khouri I, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS (2010) NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant 16: 1325-1346.
  16. Dreger P, Ritgen M, Böttcher S, Schmitz N, Kneba M (2005) The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile? Leukemia 19: 1135-1138.
 
 
zurück zur Übersicht
Corporate Partners - Individual Sponsors
Mon, 20th June 2022 to Tue, 21th June 2022
Phase I/II Meeting
more dates
Mon, 24th January 2022
New members of the European MCL board
more news